Efficacy of monoclonal antibodies against SARS-CoV-2 variants

01.02.2023

Monoclonal antibodies authorised for the prevention or treatment of COVID-19 show a decrease in activity against SARS-CoV-2 variants in vitro. The impact of these data on the clinical benefit have not been fully explained. There is a possibility that the antibodies are not effective against current variants. No data on clinical efficacy against current Omicron subvariants from randomised controlled studies are available at present for the authorised monoclonal antibodies. 

The characteristics of the circulating SARS-CoV-2 viruses, including local epidemiology and all currently available information and official recommendations, should be taken into account at the time of practical use of monoclonal antibodies for prevention or treatment of COVID-19.